J&J 1Q08 1Q Revenues: $16.2 billion (+8%) 1Q Earnings: $3.6 billion (+22%) Comments: Pharmaceutical sales rose 3% to $6.4 billion, hurt by regulatory and safety issues for Procrit, as well as generic competition for Risperdal, Duragesic and Aciphex. U.S. pharma sales were up 1% to $4.1 billion, while international sales, aided in part by currency rates, were up 8% to $2.4 billion. Global sales of Remicade grew 37% to $1.0 billion....